bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Collagen I weakly interacts with the Œ≤-sheets of Œ≤ 2 microglobulin and enhances conformational exchange to
induce amyloid formation
Cody L. Hoop1, Jie Zhu1, Shibani Bhattacharya2, Caitlyn A. Tobita1, Sheena E. Radford*,3, Jean Baum*,1
1

Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, New Jersey 08854, USA; 2New York Structural
Biology Center, New York, New York 10027, USA; and 3Astbury Centre for Structural Molecular Biology and School of Molecular
and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK
ABSTRACT: Amyloidogenesis is significant in both protein function and pathology. Amyloid formation of folded, globular proteins is
commonly initiated by partial unfolding. However, how this unfolding event is triggered for proteins that are otherwise stable in their native
environments is not well understood. The accumulation of the immunoglobulin protein Œ≤2-microglobulin (Œ≤2m) into amyloid plaques in the
joints of long-term hemodialysis patients is the hallmark of Dialysis Related Amyloidosis (DRA). While Œ≤2m does not form amyloid
unassisted near neutral pH in vitro, the localization of Œ≤2m deposits to joint spaces suggests a role for the local extracellular matrix (ECM)
proteins, specifically collagens, in promoting amyloid formation. Indeed, collagen and other ECM components have been observed to
facilitate Œ≤2m amyloid formation, but the large size and anisotropy of the complex, combined with the low affinity of these interactions, has
limited atomic-level elucidation of the amyloid-promoting mechanism by these molecules. Using solution NMR approaches that uniquely
probe weak interactions and large complexes, we are able to derive binding interfaces for collagen I on Œ≤2m and detect collagen I-induced ¬µs‚Äì
ms timescale dynamics in the Œ≤2m backbone. By combining solution NMR relaxation methods and 15N-dark state exchange saturation transfer
experiments, we propose a model in which weak, multimodal collagen I‚ÄìŒ≤2m interactions promote exchange with a minor population of an
amyloid-competent species to induce fibrillogenesis. The results portray the intimate role of the environment in switching an innocuous
protein into an amyloid-competent state, rationalizing the localization of amyloid deposits in DRA.

INTRODUCTION
Several proteins self-associate into amyloid fibrils, which in some cases have functional roles1-3, but for others are associated with
debilitating human diseases4-6 including Alzheimer‚Äôs Disease, Parkinson‚Äôs Disease, Huntington‚Äôs Disease, type II diabetes, cataracts, and
Dialysis Related Amyloidosis (DRA). The protein precursors of amyloid diseases have unrelated primary sequences and structures7, spanning
natively unfolded (intrinsically disordered) states, such as Œ±-synuclein, amyloid-Œ≤ peptide, and tau8-10, to stable, globular proteins, such as Œ≤2microglobulin (Œ≤2m), transthyretin, and immunoglobulin light chains11-13. Initiation of amyloid formation of the latter class of proteins
requires unfolding or partial unfolding of monomeric precursors, which can transiently assume amyloid-competent state(s). This kinetic
barrier may be lower for intrinsically disordered proteins. However, what triggers the initial unfolding and subsequent amyloidogenesis of
natively folded globular proteins remains poorly understood.
Accumulation of Œ≤2m amyloid plaques in the joints of long-term hemodialysis patients leads to DRA and arthritic symptoms14-17. In healthy
individuals, Œ≤2m dissociates from the major histocompatibility complex-I (MHC-I), is released into the plasma, and is carried to the kidneys
for degradation18-19. However, when hemodialysis or peritoneal dialysis are required due to kidney failure, Œ≤2m is not efficiently removed
from the plasma, leading to increased concentrations by up to 60-fold16, 20-21. Remarkably, despite being transported throughout the body, Œ≤2m
accumulates into amyloid plaques specifically in skeletal tissues of dialysis patients16, 21-24. The mechanism(s) by which Œ≤2m fibrillizes in vivo
is not well understood, since in isolation the wild-type protein (the major culprit of DRA) resists amyloid formation in physiological
conditions, even at high (100 ¬µM) concentrations25-26. It has been proposed that Œ≤2m amyloid localized in the joints could result, at least in
part, from interactions with the major components of the extracellular matrix (ECM) in bone and cartilage: collagens I and II20-23 and
glycosaminoglycans (GAGs)27-29. The binding affinities of Œ≤2m to these collagens have been shown to be in the ¬µM‚ÄìmM range30 with
preference for collagen I27. Although the interaction is weak, it is nonetheless pathologically significant, as images of ex vivo DRA plaques
reveal Œ≤2m amyloid covering the surface of collagen I fibrils21. Indeed, recent kinetics studies have revealed that ECM components, such as
collagens21, 28-29 and GAGs28-29, 31-32, as well as pre-formed fibril seeds and other co-factors25-26, 28, 31-49, induce and modulate Œ≤2m amyloid
formation. However, atomic details of how these components interact with, and induce, the amyloid formation of Œ≤2m have remained an open
question.
The weak nature of the interaction and large, anisotropic shape of the Œ≤2m‚Äìcollagen I complex create a challenge for deriving atomic-level
information on how collagen I‚ÄìŒ≤2m interactions initiate Œ≤2m amyloidogenesis. The immunoglobulin fold of monomeric Œ≤2m has dimensions
of ~ 4 nm x 2 nm x 2 nm, whereas the simplest triple helical unit of collagen I has strikingly larger dimensions of 300 nm x 1.5 nm x 1.5 nm.

1

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Collagen I triple helices assemble into even larger, structured fibrils that have diameters ranging from 10‚Äì500 nm and lengths on the ¬µmscale. Collagen I therefore presents as a large surface with numerous reactive groups for Œ≤2m interactions. These challenges are not
insurmountable, however, as powerful solution nuclear magnetic resonance (NMR) spectroscopy methods can indirectly probe large, lowly
populated complexes in site-specific detail that are invisible by other biophysical techniques.
In this study, by utilizing NMR spectroscopy experiments designed to probe large complexes, we are able to pinpoint the binding interface
of wild-type Œ≤2m for collagen I at physiological pH and have shown it to involve both Œ≤-sheets of the native protein, suggestive of different
binding modes for the same molecular complex. Residues identified at the binding interface include both hydrophobic and hydrophilic
sidechains. Through 15N relaxation experiments, we have also found that collagen I increases the number of residues in Œ≤2m involved in
conformational exchange on the ¬µs‚Äìms timescale. These regions include residues 6‚Äì11 (Œ≤-strand A), 36‚Äì39 (Œ≤-strand C), 51 (Œ≤-strand D), and
91‚Äì94 (Œ≤-strand G) in the edge Œ≤-strands and loop residues 15‚Äì20 (loop AB), 35 (loop BC), 52-53 (loop DE), 63 (loop DE), and 78 (loop EF),
the dynamics and conformations of which are known to be important for Œ≤2m amyloid formation31, 38, 50-51. We propose that the weak
interactions of collagen I with the Œ≤2m Œ≤-sheets promote exchange of the native protein with a minor population of amyloid-competent
species that induce fibrillogenesis. This study illuminates how a protein component, collagen I, local to the environment in which Œ≤2m
plaques are found, can interact with a stable, globular protein to initiate debilitating amyloid formation.

RESULTS
Collagen I induces Œ≤2m amyloid formation in a concentration-dependent manner.
Since the direct interaction of Œ≤2m with collagen in the joint space has been proposed to induce Œ≤2m amyloid formation21, 27, we probed the
Œ≤2m‚Äìcollagen I interaction under physiological pH conditions (pH 7.4) using a solid-phase enzyme-linked immunosorbent assays (ELISA)
(Figure 1A). Importantly, the results suggest a dose-dependent interaction of the two proteins, consistent with previously published results27,
under the conditions employed here. The adhesion of Œ≤2m to casein was monitored as a negative control, for which no significant binding was
observed (Figure 1A).
Having verified the Œ≤2m‚Äìcollagen I interaction under physiological pH conditions, we next monitored amyloid growth of Œ≤2m in the
presence or absence of collagen I by thioflavin T (ThT) fluorescence (Figure 1B). In the presence of 3.4 mg/ml collagen I (1:0.1 molar ratio
Œ≤2m:collagen I), Œ≤2m amyloid is formed within 12‚Äì21 days (Figure 1B, blue), as evident by enhanced ThT fluorescence. This is not observed
in the absence of collagen I in the same conditions, and collagen I alone does not show ThT fluorescence enhancement (Figure 1B). Notably,
at lower concentrations of collagen I, lower Œ≤2m concentrations, or shorter timescales fibrils are not observed29, 31. Atomic force microscopy
(AFM) images also show that Œ≤2m interacts with collagen I fibrils, with Œ≤2m coating the collagen I fibril surface before detectable fibril
formation by ThT fluorescence, obscuring the characteristic collagen I fibril D-banding that is clearly observed in the absence of Œ≤2m (Figure
1C,D), consistent with previous results21. Œ≤2m alone (Figure 1E) does not aggregate in the conditions employed, with no fibrils or high
molecular weight assemblies observed by AFM. These data confirm that adhesion of collagen I to Œ≤2m induces Œ≤2m amyloid formation under
physiological conditions in vitro, while the protein is not able to form amyloid in the absence of collagen I.

Figure 1. Detection of collagen I-driven Œ≤2m amyloid formation. (A) ELISA probing dose-dependent adhesion of Œ≤2m (10‚Äì80 ¬µg/ml) to collagen I
(10 ¬µg/ml) or casein (10 ¬µg/ml, used as a negative control), at pH 7.4. The average absorbance at 450 nm from triplicates within the same plate are
reported with the standard deviation given as error bars. (B) ThT fluorescence curves of 85 ¬µM Œ≤2m (black), 85 ¬µM Œ≤2m + 3.4 mg/ml (8.5 ¬µM)
collagen I (blue), or 3.4 mg/ml collagen I alone (orange) over 22 days in 10 mM sodium phosphate buffer, pH 7.4, shaking at 600 rpm at 37¬∞C. Three
representative curves are given for each condition. The insert shows a zoom-in of the baseline of the ThT fluorescence curves to highlight the lack of
fluorescence enhancement for both Œ≤2m (black) and collagen I (orange). (C‚ÄìE) Representative amplitude-modulated AFM images of (C) Œ≤2m coincubated with collagen I fibrils, (D) collagen I fibrils alone, and (E) Œ≤2m alone after incubating for four days at 37¬∞C with shaking.

Weak, but specific Œ≤2m‚Äìcollagen I interactions observed through 15N-R2 perturbations.

2

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

In order to understand mechanistic details by which collagen I interacts with Œ≤2m to initiate amyloid formation, we used solution NMR
methods, which provide an excellent toolbox of approaches able to characterize residue-specific features of weak protein‚Äìprotein interactions
on multiple timescales52-55. A titration of collagen I into a Œ≤2m monomer solution showed no significant chemical shift perturbations in 1H‚Äì
15
N heteronuclear single quantum correlation (HSQC) spectra (Figure S1). However, a residue-specific attrition of the peak intensities
observed with increasing collagen I concentrations (Figure 2A), suggests chemical exchange between the bound and free states of Œ≤2m
consistent with the low affinity of the interaction in these conditions (Kd ‚âà 410 ¬µM30). To minimize collagen I aggregation during the NMR
experiments and to capture the most specific interactions, we proceeded with low collagen I concentrations (0.6‚Äì1.2 mg/ml) that displayed
consistent residue-specific perturbations and kept samples at 10¬∞C, allowing NMR spectra to be acquired for over one week without visible
alterations in spectral quality. Addition of 1.2 mg/ml collagen I to 300 ¬µM Œ≤2m resulted in a reduction in resonance intensity of all peaks,
consistent with transient formation of a high molecular weight complex (Figure 2A). However, the greatest reduction in peak intensities
occurred for residues in the eight Œ≤-strands of the wild-type protein (Figure 2A). These peak intensity losses are in part due to increased 15Ntransverse relaxation rates (R2), which are sensitive to changes in internal motions on the ps‚Äìns timescale and conformational exchange on
the ¬µs‚Äìms timescale. Indeed, at these concentrations, we observe an overall increase in 15N-R2, but importantly, the increase is not uniform
across all residues, but is residue specific, involving predominantly residues 2‚Äì3 (N-terminus), 7‚Äì11 (Œ≤-strand A), 16‚Äì19 (loop AB), 23‚Äì26
(Œ≤-strand B), 35‚Äì39 (Œ≤-strand C), 50‚Äì52 (Œ≤-strand D), 64, 66‚Äì69 (Œ≤-strand E), 79‚Äì82 (Œ≤-strand F), 85, 87 (loop FG), and 91‚Äì94 (C-terminal Œ≤strand G) (Figure 2B-C). The increased 15N-R2 at these specific sites could have multiple origins, arising due to reduced backbone mobility
upon direct interaction with collagen I and/or to line broadening due to exchange between species with different chemical shifts, especially
since the observed 15N-ŒîR2 is dependent on magnetic field (700 MHz vs. 900 MHz, Fig. S2). In order to disentangle these contributions to
the increase in 15N-R2, we proceeded with two sets of NMR experiments: 15N-dark state exchange saturation transfer (DEST) experiments,
which can identify residues interacting with the large complex, and in-phase Hahn-echo experiments, which detect conformational exchange
on the ¬µs‚Äìms timescale.

Figure 2. Characterizing residue-specific Œ≤2m‚Äìcollagen I binding through 15N-R2 measurements. (A) Amide backbone signal intensity ratios
from 1H‚Äì15N HSQC spectra of 300 ¬µM Œ≤2m in the presence of 1.2 mg/ml collagen I compared with in the absence of collagen I (gray bars). The red
line is a smoothened curve of the signal intensity ratios to help guide the eye. The dashed line is drawn at the average signal intensity ratio over the
entire protein. Dips in the signal intensity reflect regions maximally perturbed by the presence of collagen I. Error bars are propagated from the noise
level of the spectra. The secondary structure is indicated above the plot. (B) 15N-R2 measurements of 300 ¬µM Œ≤2m in the presence (red) or absence
(black) of 1.2 mg/ml collagen I. The errors are propagated from the fitting errors. The dashed lines indicate the mean 15N-R2 values of Œ≤2m in the
presence or absence of 1.2 mg/ml collagen I over the entire protein. All experiments were conducted in TBS, pH 7.4 containing 0.5 mg/ml casein as
a non-specific binding blocking agent at 10¬∞C. Note that in these conditions, several residues in the DE loop do not have observable peak intensities
in the 1H‚Äì15N HSQC spectrum due to inherent conformational exchange, consistent with previous results49. (C) Solution NMR structure of the WTŒ≤2m monomer (PDB: 2XKS49) highlighting residues that show an increase in 15N-R2 higher than 13.4 s-1 (the mean Œî15N-R2) upon addition of 1.2
mg/ml collagen I.

Pinpointing the collagen I interaction interface on Œ≤2m through 15N-DEST.
In order to determine which residues of Œ≤2m interact most intimately with collagen I, we used 15N-DEST experiments56-57. This experiment
is optimal when there is a measurable increase in R2 due to formation of a transient, large complex that is NMR-invisible because of its high
R2 and detects the exchange between an observable ‚Äòlight‚Äô state (free monomeric Œ≤2m) and the NMR-invisible ‚Äòdark‚Äô state (the high
molecular weight collagen I‚ÄìŒ≤2m complex). In the DEST experiment, high molecular weight species with high R2 values, such as the
collagen I‚ÄìŒ≤2m complex, can be partially saturated by weak radiofrequency (RF) fields at frequency offsets where monomeric Œ≤2m is not
saturated. Saturation transfer to the observable monomeric species by chemical exchange is detected as a loss in monomeric Œ≤2m signal

3

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

intensity. The broadening of these DEST saturation profiles (reduced signal intensities at further frequency offsets) in the presence of
collagen I, relative to in its absence, is therefore indicative of residues at the interaction interface (Figure 3A‚ÄìB). The ‚Äòbroadness‚Äô of the
profiles was measured by calculating the DEST difference (Œò) for each residue, which is a measure of the relative effects of on-resonance and
off-resonance 15N saturation. Using a saturation frequency of 350 Hz, we measured Œò as: ùõ© =
15

15

!!"!"# !!!!"!"# !(!!!"# !!!!!"# )
,
!!"!"# !!!!"!"#

where ¬±30 kHz

were the most off-resonance N offsets, and N offsets of ¬±4 kHz provide enough saturation transfer from bound to unbound Œ≤2m to show
significant intensity loss without eliminating the signal in most cases. A substantial change in Œò (ŒîŒò) upon addition of collagen I is reflective
of residues at the binding interface (Figure 3A). Notably, we observe that the broadening of the DEST saturation profiles is residue-specific
and not uniform across all Œ≤2m residues, with some residues showing no change in the DEST difference in the presence of collagen I (Figure
3A‚ÄìB). Examples of DEST profiles in the presence or absence of collagen I for a residue that shows DEST due to collagen I binding (V82 in
Œ≤-strand F) and one that does not (K41 in the C‚ÄìC‚Äô loop) are given in Figure 3B. In Figure 3A, those residues with ŒîŒò larger than the mean,
and likely have the most direct contacts with the collagen in the Œ≤2m‚Äìcollagen I complex (shaded red), include residues 6‚Äì11 (Œ≤-strand A),
15‚Äì20 (loop AB), 21‚Äì26 (Œ≤-strand B), 35 (loop BC), 36‚Äì39 (Œ≤-strand C), 51 (Œ≤-strand D), 52‚Äì53 (loop DE), 63 (loop DE), 64‚Äì69 (Œ≤-strand
E), 78 (loop EF), 79‚Äì83 (Œ≤-strand F), and 91‚Äì94 (Œ≤-strand G).

Figure 3. 15N-DEST to identify collagen-binding interface on 15N-Œ≤2m. (A) ŒîŒò calculated from 15N-Œ≤2m DEST intensities at ¬±30 kHz and ¬±4kHz
15
N offsets with a 350 Hz saturation frequency in the presence or absence of collagen I (gray bars). The red line is a smoothened curve to guide the
eye. The dashed line represents the average value of ŒîŒò from all residues. The secondary structure is shown above the plot. (B) Examples of 15NDEST profiles of 300 ¬µM 15N-Œ≤2m in the presence (solid line, solid circles) or absence (dashed line, open circles) of 0.6 mg/ml collagen I. V82 in Œ≤strand F shows enhancement of the DEST effect upon addition of collagen, whereas K41 in the CC‚Äô loop does not. (C) 15N-R2bound for each residue
determined from fitting 15N-DEST profiles to the McConnell equations. (D) Examples of fit DEST profiles using the same residues as in (B). Data
points are shown as circles and the fits as solid lines (gray- 150 Hz saturation, black- 350 Hz saturation). All experiments were carried out in TBS,
pH 7.4, 10¬∞C at 700 MHz 1H Larmor frequency.

In addition, the full DEST profiles can be used to quantify residue-specific transverse relaxation values of Œ≤2m in the collagen I-bound state
(R2bound) and exchange kinetics between the bound and unbound Œ≤2m. Since the ŒîR2 may be due to more complex processes than collagen I
binding alone, such as an overall increased viscosity due to the presence of the large collagen I molecules, we fit only the 15N DEST profiles
of each residue with 150 Hz and 350 Hz RF saturation to the McConnell equations56-57. Fitting to a simple two-state model, the population of
the unbound, monomeric Œ≤2m was determined to be 94 +/- 2% with an apparent first-order rate constant for the conversion of Œ≤2m from
unbound to collagen I-bound conformation (konapp) of 6.4 +/- 0.8 s-1. We interpret the direct binding interface to be the residues with the
highest R2bound. The 15N-R2bound profile shows a similar trend to the ŒîŒò profile (Figure 3A, C), and suggests that binding interfaces for
collagen I on Œ≤2m occur on both Œ≤-sheets. Examples of fitting to the experimental values of residues V82 (in a binding region) and K41 (away
from interface) are shown in Figure 3D.
Collagen I induced conformational exchange in Œ≤2m revealed by 15N relaxation.
The enhanced 15N-R2 of Œ≤2m may not only be due to binding with a high molecular weight species (such as in a large complex), but also to
an increase in conformational exchange dynamics of Œ≤2m on the ¬µs‚Äìms timescale, since the 15N-ŒîR2 is dependent on the magnetic field
(Figure S2). In order to determine which residues in Œ≤2m are in conformational exchange in the presence of collagen I, we use 15N in-phase
Hahn echo experiments (R2HE) to estimate the relaxation exchange rates. At pH 7.4 and 10¬∞C, few residues in Œ≤2m have Rex values greater
than 10s-1 in the absence of collagen I as measured by the in-phase Hahn echo experiments (Figure 4A). The N-terminus and residues in the
BC and DE loops (for which several signals are unobservable) are natively in conformational exchange (Figure 4A). Upon addition of 0.6

4

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

mg/ml collagen I, the regions with high Rex are expanded to include the full N-terminal Œ≤-strand A, part of Œ≤-strand B to part of Œ≤-strand C,
including the connecting BC loop, Œ≤-strand D, the DE loop, the C-terminal end of Œ≤-strand F into the FG loop, and the C-terminal Œ≤-strand G
(Figure 4B). Conformational dynamics in specific regions of Œ≤2m, including the N-terminal region and the BC loop that contains cis Pro32,
have been shown to be crucial in controlling the amyloidogenicity of the protein49, 58. Thus, the enhanced conformational exchange induced
by the presence of collagen I may facilitate minor populations of amyloid-component states of Œ≤2m.

Figure 4. Conformational exchange in Œ≤2m induced by collagen I. Relaxation exchange rates (Rex) obtained by 15N-R2 Hahn echo experiments for
each residue in 300 ¬µM 15N-Œ≤2m in the absence (A) or presence (B) of 0.6 mg/ml collagen I at pH 7.4, 10¬∞C, 700 MHz 1H Larmor frequency. Rex
values over 10 s-1 are indicated in blue bars. Regions shaded in cyan in both panels contain several residues with Rex >10 s-1 in the respective
conditions. Residues with unobservable cross-peaks are indicated by open circles. Residues that were observable in the absence of collagen I but
were reduced to the level of the noise in the presence of collagen I are indicated by filled blue circles. Error bars are propagated from fitting errors.

DISCUSSION
A novel collagen I binding surface on Œ≤2m.
Amyloid formation of Œ≤2m at physiological pH in vitro requires assistance by co-factors21, 25-26, 28-29, 31-49. In particular, ECM molecules, such
as collagens and GAGs have been targeted as amyloid-inducing co-factors, since Œ≤2m amyloid formation has been localized to
musculoskeletal tissues16, 22-24. While previous experiments have focused on the kinetics of amyloid formation in the presence of these
molecules21, 28-29, 31, 59, a detailed atomistic description of the interactions involved and how these may enhance Œ≤2m conformational dynamics
and amyloid formation had not been elucidated. Here, we have used complementary NMR relaxation-based experiments to pinpoint residues
of Œ≤2m involved in the collagen I binding interface and collagen I-induced dynamics that lead to enhanced Œ≤2m amyloid formation at neutral
pH in vitro. The 15N-DEST experiments indicate that residues in Œ≤-strands A, B, C, D, E, F, and G form interaction surfaces with collagen I.
These provide two surfaces of mixed hydrophilic and hydrophobic composition (Fig. S3). Both contain hydrophobic patches with the ABED
Œ≤-sheet displaying several aromatic residues on the interaction surface (Fig. S3). Since both Œ≤-sheets on opposite sides of the molecule were
determined to interact with the collagen I surface, binding must be multimodal involving interaction surfaces formed by K6, Q8, Y10, F22,
N24, Y26, S52, Y63, L65, Y67, and E69 on the ABED Œ≤-sheet and E36, D38, L40, A79, R81, N83, I92, and K94 on the GFC Œ≤-sheet (Figure
3, S3). Comparison of the molecular dimensions of the interacting molecules (4 x 2 x 2 nm for Œ≤2m, 300 nm x 1.5 nm for a collagen I triple
helix, and microns in length x up to 500 nm in diameter for mature collagen I fibrils) highlights the potential for a myriad of binding modes,
enabling independent binding of several Œ≤2m molecules to the same collagen molecule (Figure 5A‚ÄìB). Importantly, the collagen I triple helix
surface is interspersed with numerous hydrophilic and hydrophobic residues along its length (Figure 5A). The collagen I fibril surface
maintains this repeating pattern of surface chemistries (Figure 5B), enhancing the potential for multiple binding modes to complementary
surfaces in Œ≤2m (Figure 5C).

5

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 5. Potential surface contacts for Œ≤2m‚Äìcollagen I interaction. A) Surface model of the collagen I monomer (PDB: 3HKS60) color-coded by
amino acid type (top: hydrophilic, bottom: hydrophobic). A surface representation of Œ≤2m is shown for size comparison (PDB: 2XKS49). As an
example, electrostatic surfaces of Œ≤2m are shown weakly interacting with electrostatic surfaces of collagen I. (B) Surface models of the collagen I
fibril repeating unit (built from PDB: 3HKS60), color-coded by amino acid type (top: hydrophilic, bottom: hydrophobic). The repeating unit is ~67
nm in length, however mature fibrils can be microns long and ~500 nm in diameter. Distinct bands of electrostatic residues are observed within the
repeating unit. (C) Surface representation of Œ≤2m monomer (PDB: 2XKS49) color-coded by amino acid type (left: hydrophilic, right: hydrophobic).
All models are color-coded as: red, acidic; blue, basic; purple, uncharged-polar; and green, hydrophobic.

Collagen I is known to interact with multiple immunoglobulin-like protein folds through binding interfaces that include both hydrophobic
and hydrophilic residues. Interactions of collagen I with osteoclast-associated receptor (OSCAR), leukocyte-associated immunoglobulin-like
receptor-1 (LAIR-1), and glycoprotein VI (GPVI), play functional roles in immune system regulation61-64 and platelet activation65-67. Similar
to the Œ≤-sheet binding interface on Œ≤2m for collagen I identified here, the collagen I binding sites on OSCAR and LAIR-1 are also found in Œ≤sheet regions68-69. In the case of the OSCAR‚Äìcollagen I interactions, Tyr and Arg residues that line the interacting Œ≤-sheet of OSCAR have
been suggested to play a primary role68. LAIR-1 binds primarily to collagen fragments rich in Gly, Pro and hydroxyproline (GPO) content,
but also has been shown to interact with multiple binding motifs in collagen II and III toolkit peptides, some of which are not GPO rich69.
NMR and mutagenesis studies on LAIR-1 have shown that depletion of Arg or Glu at the putative Œ≤-sheet interface showed decreased
collagen binding, suggesting a role for electrostatic interactions70. GPVI, also recognizes GPO rich collagen motifs, however through a
unique hydrophobic groove formed by a Œ≤-strand connecting loop that is flanked by hydrophilic residues71-73. Thus, although these proteins
all share a similar immunoglobulin fold, each shows a unique binding interface to collagen, interacting in grooves formed by Œ≤-sheets or
loops and having both hydrophobic and hydrophilic residues that each play fundamental roles in binding.
Collagen-induced conformational dynamics in Œ≤2m reflect amyloid prone dynamics.
Beyond the structured collagen I-binding interface of Œ≤2m, using 15N relaxation experiments, we observe enhanced dynamics in the N- and
C- termini, BC and FG loops, and the Œ≤-strand D of Œ≤2m upon complex formation. Enhanced dynamics in each of these regions has been
proposed to play key roles in the aggregation mechanism of wild-type Œ≤2m38, 49-51, 74-84. Amyloid formation of Œ≤2m is nucleation dependent and
proceeds through a near native folding intermediate, IT, that is in part defined by a non-native trans-His31-Pro32 peptide bond in the BC
loop38, 50-51, 85-86. The cis-trans isomerization of Pro32 is aided by displacement of the N-terminal six residues, which destabilizes the BC loop,
allowing Œ≤2m to sample multiple amyloidogenic conformations that enhance the rate of aggregation38, 50-51, 74, 79-81, 85-86. Deletion of the first six
N-terminal residues in the naturally occurring variant, ŒîN6, enhances the propensity for amyloid formation, and aggregation occurs in the
absence of additional cofactors at physiological pH in vitro49, 74, 87-88. In addition, NMR relaxation experiments show enhanced dynamics in Œ≤strand D and the DE loop of amyloidogenic ŒîN649, which have been proposed to contribute to its higher aggregation propensity. NMR
studies of a P32G-Œ≤2m variant, which inherently has a trans-His31-Gly32 peptide bond, showed significant line broadening in Œ≤-strands A
and D and the BC and FG loops relative to WT-Œ≤2m38. This was interpreted to result from conformational conversion between the native and
IT conformations38. The observation of increased Rex of these same regions upon addition of collagen I to WT-Œ≤2m, in this study, is consistent
with the same regions undergoing conformational exchange from the native state to an amyloidogenic precursor consistent with the IT state,
to enhance amyloid formation. Such a model provides a mechanism to enhance cis-trans Pro isomerization to initiate assembly into amyloid
without the involvement of a prolyl isomerase.
A proposed mechanism of collagen I-driven Œ≤2m amyloidogenesis.

6

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

With the new insights into the binding interface of collagen I on Œ≤2m and its impact on Œ≤2m dynamics described here, we propose a
mechanistic view of how collagen I drives amyloidogenesis of Œ≤2m. In the presence of collagen I, the Œ≤-sheets of Œ≤2m are available for
binding to the collagen I surface, with both Œ≤-sheets providing potential binding interfaces, indicative of multiple binding modes, rather that a
unique and specific binding interface. The interaction between the two molecules is mediated by hydrophobic and electrostatic interactions
(Figures 3, S3). In its native state, high transverse relaxation rates are observed in the apical loops of Œ≤2m, including the BC loop that contains
cis Pro32 and the adjacent DE loop (Figure 2B). Additional dynamics upon collagen I binding are imposed on the N-terminus, Œ≤-strands B
and C, BC loop, Œ≤-strand D, FG loop, and the C-terminal Œ≤-strand G (Figure 4B). Through modification of the dynamics of Œ≤2m in these sites,
the probability of cis-trans isomerization of Pro32, known to be a key step in Œ≤2m fibril formation85-86, will be increased, with concomitant
sampling of amyloid-competent species, including the IT state, known to promote amyloid formation38, 50-51 (Figure 6). The results provide a
molecular explanation for the mechanism of deposition of Œ≤2m in collagenous-rich joints in dialysis patients16, 21-24. More generally, they also
serve as an exemplar of the key role of the physiological environment in amyloid formation, by rationalizing the often remarkably specific
deposition of amyloid to different tissues1, and in some cases, of different variants of the same protein in different tissues89-90. The methods
used here to interrogate the weak-transient interaction of the large, Œ≤2m‚Äìcollagen I complex can be extended to future studies to gain atomiclevel insight into how other physiologically relevant cofactors promote amyloid formation of globular proteins involved in other amyloid
diseases.

Figure 6. Proposed mechanism for collagen-driven Œ≤2m amyloidogenesis. Alone, the Œ≤2m monomer (PDB: 2XKS49) does not readily aggregate
into amyloid fibrils. Upon addition of collagen I, we have observed an interaction interface to include both Œ≤-sheets of Œ≤2m through the 15N-DEST
experiment (red). Collagen also induces conformational exchange in regions colored in blue, as assessed by 15N relaxation experiments. The
interaction of collagen I with the structured regions of Œ≤2m enhances conformational exchange, promoting formation of an amyloid-competent
species and inducing aggregation.

MATERIALS AND METHODS
Expression and purification of Œ≤2m.
Wild-type Œ≤2m was expressed recombinantly in Escherichia coli BL21(DE3) pLysS cells by induction with 1 mM IPTG overnight at 37¬∞C,
following methods described previously39. Cells were lysed in 25 mM Tris-HCl buffer, pH 8.0 and with an Avestin Emulsiflex-C5
homogenizer. Œ≤2m is accumulated in inclusion bodies. To extract the Œ≤2m from inclusion bodies, the cell pellet was washed five times with 25
mM Tris-HCl buffer, pH 8.0 and solubilized in 25 mM Tris-HCl, pH 8.0 buffer containing 8 M urea, rocking overnight at room temperature.
The protein was verified to be in the soluble fraction by SDS-PAGE. Œ≤2m was refolded by dialyzing against 25 mM Tris-HCl buffer, pH 8.0
at 4¬∞C and purifying by anion exchange (HiTrap Q HP, GE Healthcare). The protein was further purified by size exclusion chromatography
with a Superdex 75 gel filtration column (GE Life Sciences). Protein purity was verified by SDS-PAGE, and concentrations for experiments
were determined by measuring the absorbance at 280 nm using a molar extinction coefficient of 19,060 M-1cm-1. [U-15N]-enriched Œ≤2m was
expressed recombinantly for NMR using the same protocol in HCDM1 minimal media supplemented with 15N-ammonium chloride.
ELISA.
Relative adhesion of variable concentrations of Œ≤2m to collagen I was determined by ELISA experiments. Nunc Maxisorp 96-well plates
(Thermo Scientific) were coated with 100 ¬µl of collagen I from rat tail tendon (BD Biosciences; 10 ¬µg/ml in 10 mM acetic acid) overnight at
4¬∞C. Uncoated areas on the plates were blocked with 200 ¬µl of 0.5% w/v casein in binding buffer at room temperature for 1 hr. The binding
and washing buffer consisted of PBS at pH 7.4 with 0.05% v/v Tween 20 (PBS-T) and 0.05% w/v casein as a non-specific blocking agent.
After washing the wells three times with 200 ¬µl washing buffer, 100 ¬µl Œ≤2m in PBS-T and 0.05% w/v casein (10 ¬µg/ml, 40 ¬µg/ml, or 80

7

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

¬µg/ml) was added to the wells and incubated for 1 hr at room temperature. After three washes with 200 ¬µl washing buffer, 100 ¬µl mouse antiŒ≤2m monoclonal antibody (1:2000 v/v in PBS-T and 0.05% w/v casein, Millipore Sigma) was bound to Œ≤2m in each well by incubating at
room temperature for 1 hr. Subsequently, following three washes with 200 ¬µl washing buffer, 100 ¬µl of goat HRP-conjugated anti-mouse
secondary antibody (1:5000 v/v dilution in PBS-T and 0.05% w/v casein, Genscript) was incubated in the wells at room temperature for 30
min. After washing for a final four times with 200 ¬µl washing buffer, the binding of Œ≤2m to collagen I was detected through a colorimetric
assay using a 3,3‚Äô,5,5‚Äô-tetramethylbenzidine substrate kit (Pierce) according to the manufacturer‚Äôs protocol, and measuring the absorbance at
450 nm using a Tecan Infinite F50 plate reader with Magellan software.
ThT fluorescence.
Amyloid fibril formation was monitored by ThT fluorescence assays of Œ≤2m in the presence or absence of collagen I fibrils. Purified
recombinant Œ≤2m lyophilized powder was dissolved in 100 ¬µl of 10 mM sodium phosphate buffer, pH 7.4 to 1 mg/ml (85 ¬µM). Collagen I
fibrils were prepared by incubating 3.4 mg/ml collagen I (BD Biosciences) in PBS, pH 7.4 at 37¬∞C for 1 hr. The fibril suspension was
sonicated in a bath sonicator for 10 min and centrifuged at 16,500 rpm for 10 min to isolate fibrils. Collagen fibril pellets were resuspended in
100 ¬µl of 10 mM sodium phosphate buffer, pH 7.4 in the presence or absence of Œ≤2m. Three or four samples were prepared for each condition
and were transferred to a 96-well plate. ThT was added to each sample to a final concentration of 10 ¬µM. ThT fluorescence was monitored
over 22 days at 37¬∞C with shaking at 600 rpm in a POLARstar Omega fluorimeter (BMG Labtech).
NMR.
For all NMR experiments, purified recombinant [U-15N]-labeled Œ≤2m was diluted to 300 ¬µM in TBS, pH 7.4 with 0.5 mg/ml casein and
10% v/v D2O. Before mixing, collagen I from rat tail tendon was dialyzed against TBS, pH 7.4. The concentration of collagen I after dialysis
was determined by bicinchoninic acid assay (Pierce). All experiments were performed at 10¬∞C. All data were collected on a 700 MHz Bruker
AVIII or 900 MHz AVI NMR spectrometers equipped with TCI-cryo-probes. Data were processed in NMRPipe91 and analyzed in Sparky92.
1
H-15N HSQC spectra
1
H-15N HSQC spectra93-94 of [U-15N]-labeled Œ≤2m were acquired with different concentrations of collagen I (0, 0.12 mg/ml, and 1.2 mg/ml)
in TBS, pH 7.4 with 0.5 mg/ml casein and 10% D2O at 10¬∞C. The intensity ratio is taken as the intensity of a given cross-peak in the 1H-15N
HSQC spectrum of Œ≤2m in the presence of collagen I relative to the intensity of the same cross-peak in the absence of collagen I, determined
in Sparky92. The errors were propagated from the signal to noise ratio in each spectra.
15
N-R2 and 15N-R2HE
[U-15N]-labeled Œ≤2m 15N transverse relaxation rates (R2) were measured from a series of HSQC-based 2D 1H-15N spectra using the CarrPurcell-Meiboom-Gill (CPMG) pulse sequence95 with varying relaxation delays: in the absence of collagen I at 700 MHz- 0, 16, 16, 32, 48,
64, 64, 80, 96, and 112 ms and 900 MHz- 0, 16, 32, 32, 32, 48, 64, 80, 96, 112, and 128 ms and in the presence of 1.2 mg/ml collagen I at
700 mHz- 0, 16, 16, 32, 48, 48, 64, and 80 ms and at 900 MHz- 0, 16, 32, 32, 32, 48, 64, 80, and 96 ms. Relaxation delays used to quantify
15
N-R2 rates of Œ≤2m in the presence of 0.6 mg/ml collagen I at 700 MHz were: 0, 8, 8, 16, 24, 32, and 56 ms and in the absence of collagen I:
0, 8, 8, 16, 24, 40, and 56 ms. 15N-R2HE informs on the chemical exchange contribution to R2 by using an in-phase Hahn echo experiment96.
Relaxation delays used in the R2HE experiment both in the presence and absence of 0.6 mg/ml collagen I were: 0.768, 7.68, 7.68, 15.4, 23,
38.5, and 61.4 ms. In each case, the R2 rates were determined by fitting peak intensities to a single exponential decay function. The chemical
exchange contribution (Rex) for each Œ≤2m residue in the absence and presence of 0.6 mg/ml collagen I was determined as: Rex = R2HE-R2.
DEST experiments
The 15N-DEST experiment56-57 was applied to [U-15N]-labeled Œ≤2m in the presence or absence of 0.6 mg/ml collagen I. In this experiment,
an 15N saturation pulse of 150 or 350 Hz was applied for 0.9 ms at different 15N frequency offsets: 0, ¬±1, ¬±2, ¬±4, ¬±8, ¬±14, ¬±21, and ¬±30 kHz.
An experiment in which the 15N saturation pulse was set to 0 Hz with an offset of 30 kHz was also included as a reference. The 15N-DEST
profiles were extracted for each residue as the peak intensity at each 15N saturation offset and were fitted to a two-state model using the destfit
program by Clore and co-workers to obtain R2bound, pbound, and konapp56-57. The ŒîŒò profile was obtained by measuring Œò for each Œ≤2m residue in
!
!!
!(!
!!
)
the presence and absence of 0.6 mg/ml collagen I as: ùõ© = !"!"# !!"!"# !!"# !!!"# , and taking ŒîŒò = Œò+col ‚Äì Œò-col.
!!"!"# !!!!"!"#

ASSOCIATED CONTENT
Supporting Information
The Supporting Information includes figures that show an overlay of 1H-15N HSQC spectra of [U-15N]-Œ≤2m in the presence of 0 mg/ml, 0.12 mg/ml,
or 1.2 mg/ml collagen I (Figure S1); 15N-R2 measurements of [U-15N]-Œ≤2m in the absence or presence of collagen I at 700 MHz or 900 MHz (Figure
S2); and a model showing the amino acid composition of the interacting Œ≤2m Œ≤-sheets (Figure S3). (PDF)

AUTHOR INFORMATION
Corresponding Author
*Jean Baum, jean.baum@rutgers.edu or Sheena E. Radford, s.e.radford@leeds.ac.uk

Notes
The authors declare no competing financial interests.

8

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Funding Sources
This work was supported by American Heart Association Postdoctoral Fellowship 17POST33410326 to CLH and NIH grant GM45302 to JB.
Additional support was provided by the Wellcome Trust (204963 and 092896) and the European Research Council (ERC) under European Union‚Äôs
Seventh Framework Programme (FP7/2007-2013) ERC grant agreement no. 322408 to SER. Some of the work presented here was conducted at the
Center on Macromolecular Dynamics by NMR Spectroscopy located at the New York Structural Biology Center, supported by a grant from the NIH
NIGMS (P41 GM118302) and ORIP/NIH facility improvement grant CO6RR015495. The 900 MHz NMR spectrometers were purchased with funds
from NIH grant P41 GM066354, the Keck Foundation, New York State Assembly, and U.S. Dept. of Defense.

ACKNOWLEDGMENT
We acknowledge Arthur Palmer for helpful discussions. We also acknowledge with thanks the many discussions with our group members. We thank
Ana Monica Nunes for contributions in the beginning of this project and Nuria Benseny-Cases, who provided critical insights in the early stages of
the work.

ABBREVIATIONS
Œ≤2m, Œ≤2-microglobulin; DRA, Dialysis Related Amyloidosis; ECM, extracellular matrix; MHC-I, major histocompatibility complex-I; GAGglycosaminoglycan; NMR, nuclear magnetic resonance; ELISA, enzyme-linked immunosorbent assay; ThT, thioflavin T; AFM, atomic force
microscopy; HSQC, heteronuclear single quantum correlation; DEST, dark-state exchange saturation transfer; OSCAR, osteoclast associated
receptor; LAIR-1, leukocyte associated immunoglobulin-like receptor-1; GPVI, glycoprotein VI; CPMG, Carr-Purcell-Meiboom-Gill.

REFERENCES
1.
Chiti, F.; Dobson, C. M., Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006, 75, 333-66.
2.
Pham, C. L.; Kwan, A. H.; Sunde, M., Functional amyloid: widespread in Nature, diverse in purpose. Essays Biochem 2014, 56, 207-19.
3.
Fowler, D. M.; Koulov, A. V.; Balch, W. E.; Kelly, J. W., Functional amyloid ‚Äì from bacteria to humans. Trends in Biochemical Sciences 2007, 32
(5), 217-224.
4.
Iadanza, M. G.; Jackson, M. P.; Hewitt, E. W.; Ranson, N. A.; Radford, S. E., A new era for understanding amyloid structures and disease. Nat Rev
Mol Cell Biol 2018, 19 (12), 755-773.
5.
Knowles, T. P.; Vendruscolo, M.; Dobson, C. M., The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol
2014, 15 (6), 384-96.
6.
Chiti, F.; Dobson, C. M., Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annu Rev
Biochem 2017, 86, 27-68.
7.
Eisenberg, D. S.; Sawaya, M. R., Structural Studies of Amyloid Proteins at the Molecular Level. Annu Rev Biochem 2017, 86, 69-95.
8.
Nizynski, B.; Dzwolak, W.; Nieznanski, K., Amyloidogenesis of Tau protein. Protein Sci 2017, 26 (11), 2126-2150.
9.
Korsak, M.; Kozyreva, T., Beta Amyloid Hallmarks: From Intrinsically Disordered Proteins to Alzheimer's Disease. Adv Exp Med Biol 2015, 870,
401-21.
10.
Darling, A. L.; Uversky, V. N., Intrinsic Disorder in Proteins with Pathogenic Repeat Expansions. Molecules 2017, 22 (12).
11.
Iannuzzi, C.; Maritato, R.; Irace, G.; Sirangelo, I., Misfolding and amyloid aggregation of apomyoglobin. Int J Mol Sci 2013, 14 (7), 14287-300.
12.
Chiti, F.; Dobson, C. M., Amyloid formation by globular proteins under native conditions. Nat Chem Biol 2009, 5 (1), 15-22.
13.
Iadanza, M. G.; Silvers, R.; Boardman, J.; Smith, H. I.; Karamanos, T. K.; Debelouchina, G. T.; Su, Y.; Griffin, R. G.; Ranson, N. A.; Radford, S.
E., The structure of a beta2-microglobulin fibril suggests a molecular basis for its amyloid polymorphism. Nat Commun 2018, 9 (1), 4517.
14.
Dember, L. M.; Jaber, B. L., Dialysis-related amyloidosis: late finding or hidden epidemic? Semin Dial 2006, 19 (2), 105-9.
15.
Dzido, G.; Sprague, S. M., Dialysis-related amyloidosis. Minerva Urol Nefrol 2003, 55 (2), 121-9.
16.
Gejyo, F.; Yamada, T.; Odani, S.; Nakagawa, Y.; Arakawa, M.; Kunitomo, T.; Kataoka, H.; Suzuki, M.; Hirasawa, Y.; Shirahama, T.; et al., A new
form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun 1985, 129 (3), 701-6.
17.
Mu√±oz-G√≥mez, J.; Bergad√°-Barado, E.; G√≥mez-P√©rez, R.; Llopart-Buis√°n, E.; Sub√≠as-Sobrev√≠a, E.; Rot√©s-Querol, J.; Sol√©-Arqu√©s, M., Amyloid
arthropathy in patients undergoing periodical haemodialysis for chronic renal failure: a new complication. Annals of the Rheumatic Diseases 1985, 44 (11),
729-733.
18.
Becker, J. W.; Reeke, G. N., Jr., Three-dimensional structure of beta 2-microglobulin. Proc Natl Acad Sci U S A 1985, 82 (12), 4225-9.
19.
Floege, J.; Bartsch, A.; Schulze, M.; Shaldon, S.; Koch, K. M.; Smeby, L. C., Clearance and synthesis rates of beta 2-microglobulin in patients
undergoing hemodialysis and in normal subjects. J Lab Clin Med 1991, 118 (2), 153-65.
20.
Homma, N.; Gejyo, F.; Isemura, M.; Arakawa, M., Collagen-binding affinity of beta-2-microglobulin, a preprotein of hemodialysis-associated
amyloidosis. Nephron 1989, 53 (1), 37-40.
21.
Relini, A.; Canale, C.; De Stefano, S.; Rolandi, R.; Giorgetti, S.; Stoppini, M.; Rossi, A.; Fogolari, F.; Corazza, A.; Esposito, G.; Gliozzi, A.;
Bellotti, V., Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J
Biol Chem 2006, 281 (24), 16521-9.
22.
Hadjipavlou, A.; Lander, P.; Begin, L.; Bercovitch, D.; Davidman, M.; Jakab, E., Skeletal amyloidosis due to beta microglobulinemia in a patient
on hemodialysis. A case report. J Bone Joint Surg Am 1988, 70 (1), 119-21.
23.
Bardin, T.; Kuntz, D.; Zingraff, J.; Voisin, M.-C.; Zelmar, A.; Lansaman, J., Synovial amyloidosis in patients undergoing long-term hemodialysis.
Arthritis & Rheumatism 1985, 28 (9), 1052-1058.
24.
Gejyo, F.; Odani, S.; Yamada, T.; Honma, N.; Saito, H.; Suzuki, Y.; Nakagawa, Y.; Kobayashi, H.; Maruyama, Y.; Hirasawa, Y.; et al., Beta 2microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 1986, 30 (3), 385-90.
25.
Eakin, C. M.; Miranker, A. D., From chance to frequent encounters: origins of beta2-microglobulin fibrillogenesis. Biochim Biophys Acta 2005,
1753 (1), 92-9.
26.
Platt, G. W.; Radford, S. E., Glimpses of the molecular mechanisms of beta2-microglobulin fibril formation in vitro: aggregation on a complex
energy landscape. FEBS Lett 2009, 583 (16), 2623-9.
27.
Moe, S. M.; Chen, N. X., The role of the synovium and cartilage in the pathogenesis of beta(2)-microglobulin amyloidosis. Semin Dial 2001, 14
(2), 127-30.

9

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

28.
Relini, A.; De Stefano, S.; Torrassa, S.; Cavalleri, O.; Rolandi, R.; Gliozzi, A.; Giorgetti, S.; Raimondi, S.; Marchese, L.; Verga, L.; Rossi, A.;
Stoppini, M.; Bellotti, V., Heparin strongly enhances the formation of beta2-microglobulin amyloid fibrils in the presence of type I collagen. J Biol Chem
2008, 283 (8), 4912-20.
29.
Benseny-Cases, N.; Karamanos, T. K.; Hoop, C. L.; Baum, J.; Radford, S. E., Extracellular matrix components modulate different stages in beta2microglobulin amyloid formation. J Biol Chem 2019, 294 (24), 9392-9401.
30.
Giorgetti, S.; Rossi, A.; Mangione, P.; Raimondi, S.; Marini, S.; Stoppini, M.; Corazza, A.; Viglino, P.; Esposito, G.; Cetta, G.; Merlini, G.;
Bellotti, V., Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Sci 2005, 14 (3), 696-702.
31.
Myers, S. L.; Jones, S.; Jahn, T. R.; Morten, I. J.; Tennent, G. A.; Hewitt, E. W.; Radford, S. E., A systematic study of the effect of physiological
factors on beta2-microglobulin amyloid formation at neutral pH. Biochemistry 2006, 45 (7), 2311-21.
32.
Yamamoto, S.; Yamaguchi, I.; Hasegawa, K.; Tsutsumi, S.; Goto, Y.; Gejyo, F.; Naiki, H., Glycosaminoglycans enhance the trifluoroethanolinduced extension of beta 2-microglobulin-related amyloid fibrils at a neutral pH. J Am Soc Nephrol 2004, 15 (1), 126-33.
33.
Srikanth, R.; Mendoza, V. L.; Bridgewater, J. D.; Zhang, G.; Vachet, R. W., Copper binding to beta-2-microglobulin and its pre-amyloid oligomers.
Biochemistry 2009, 48 (41), 9871-81.
34.
Antwi, K.; Mahar, M.; Srikanth, R.; Olbris, M. R.; Tyson, J. F.; Vachet, R. W., Cu(II) organizes beta-2-microglobulin oligomers but is released
upon amyloid formation. Protein Sci 2008, 17 (4), 748-59.
35.
Calabrese, M. F.; Miranker, A. D., Metal binding sheds light on mechanisms of amyloid assembly. Prion 2009, 3 (1), 1-4.
36.
Calabrese, M. F.; Eakin, C. M.; Wang, J. M.; Miranker, A. D., A regulatable switch mediates self-association in an immunoglobulin fold. Nat
Struct Mol Biol 2008, 15 (9), 965-71.
37.
Calabrese, M. F.; Miranker, A. D., Formation of a stable oligomer of beta-2 microglobulin requires only transient encounter with Cu(II). J Mol Biol
2007, 367 (1), 1-7.
38.
Jahn, T. R.; Parker, M. J.; Homans, S. W.; Radford, S. E., Amyloid formation under physiological conditions proceeds via a native-like folding
intermediate. Nat Struct Mol Biol 2006, 13 (3), 195-201.
39.
McParland, V. J.; Kad, N. M.; Kalverda, A. P.; Brown, A.; Kirwin-Jones, P.; Hunter, M. G.; Sunde, M.; Radford, S. E., Partially unfolded states of
beta(2)-microglobulin and amyloid formation in vitro. Biochemistry 2000, 39 (30), 8735-46.
40.
Morgan, C. J.; Gelfand, M.; Atreya, C.; Miranker, A. D., Kidney dialysis-associated amyloidosis: a molecular role for copper in fiber formation. J
Mol Biol 2001, 309 (2), 339-45.
41.
Yamamoto, S.; Hasegawa, K.; Yamaguchi, I.; Tsutsumi, S.; Kardos, J.; Goto, Y.; Gejyo, F.; Naiki, H., Low concentrations of sodium dodecyl
sulfate induce the extension of beta 2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry 2004, 43 (34), 11075-82.
42.
Borysik, A. J.; Morten, I. J.; Radford, S. E.; Hewitt, E. W., Specific glycosaminoglycans promote unseeded amyloid formation from beta2microglobulin under physiological conditions. Kidney Int 2007, 72 (2), 174-81.
43.
Gosal, W. S.; Morten, I. J.; Hewitt, E. W.; Smith, D. A.; Thomson, N. H.; Radford, S. E., Competing pathways determine fibril morphology in the
self-assembly of beta2-microglobulin into amyloid. J Mol Biol 2005, 351 (4), 850-64.
44.
Ricagno, S.; Colombo, M.; de Rosa, M.; Sangiovanni, E.; Giorgetti, S.; Raimondi, S.; Bellotti, V.; Bolognesi, M., DE loop mutations affect beta2microglobulin stability and amyloid aggregation. Biochem Biophys Res Commun 2008, 377 (1), 146-50.
45.
Santambrogio, C.; Ricagno, S.; Colombo, M.; Barbiroli, A.; Bonomi, F.; Bellotti, V.; Bolognesi, M.; Grandori, R., DE-loop mutations affect beta2
microglobulin stability, oligomerization, and the low-pH unfolded form. Protein Sci 2010, 19 (7), 1386-94.
46.
Halabelian, L.; Relini, A.; Barbiroli, A.; Penco, A.; Bolognesi, M.; Ricagno, S., A covalent homodimer probing early oligomers along amyloid
aggregation. Sci Rep 2015, 5, 14651.
47.
Leney, A. C.; Pashley, C. L.; Scarff, C. A.; Radford, S. E.; Ashcroft, A. E., Insights into the role of the beta-2 microglobulin D-strand in amyloid
propensity revealed by mass spectrometry. Mol Biosyst 2014, 10 (3), 412-20.
48.
Narang, D.; Singh, A.; Swasthi, H. M.; Mukhopadhyay, S., Characterization of Salt-Induced Oligomerization of Human beta2-Microglobulin at
Low pH. J Phys Chem B 2016, 120 (32), 7815-23.
49.
Eichner, T.; Kalverda, A. P.; Thompson, G. S.; Homans, S. W.; Radford, S. E., Conformational conversion during amyloid formation at atomic
resolution. Mol Cell 2011, 41 (2), 161-72.
50.
Kameda, A.; Hoshino, M.; Higurashi, T.; Takahashi, S.; Naiki, H.; Goto, Y., Nuclear magnetic resonance characterization of the refolding
intermediate of beta2-microglobulin trapped by non-native prolyl peptide bond. J Mol Biol 2005, 348 (2), 383-97.
51.
Sakata, M.; Chatani, E.; Kameda, A.; Sakurai, K.; Naiki, H.; Goto, Y., Kinetic coupling of folding and prolyl isomerization of beta2-microglobulin
studied by mutational analysis. J Mol Biol 2008, 382 (5), 1242-55.
52.
Janowska, M. K.; Wu, K. P.; Baum, J., Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by
beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein. Sci Rep 2015, 5, 15164.
53.
Wu, K. P.; Baum, J., Detection of transient interchain interactions in the intrinsically disordered protein alpha-synuclein by NMR paramagnetic
relaxation enhancement. J Am Chem Soc 2010, 132 (16), 5546-7.
54.
Lian, L. Y., NMR studies of weak protein-protein interactions. Prog Nucl Magn Reson Spectrosc 2013, 71, 59-72.
55.
Vinogradova, O.; Qin, J., NMR as a unique tool in assessment and complex determination of weak protein-protein interactions. Top Curr Chem
2012, 326, 35-45.
56.
Fawzi, N. L.; Ying, J.; Ghirlando, R.; Torchia, D. A.; Clore, G. M., Atomic-resolution dynamics on the surface of amyloid-beta protofibrils probed
by solution NMR. Nature 2011, 480 (7376), 268-72.
57.
Fawzi, N. L.; Ying, J.; Torchia, D. A.; Clore, G. M., Probing exchange kinetics and atomic resolution dynamics in high-molecular-weight
complexes using dark-state exchange saturation transfer NMR spectroscopy. Nat Protoc 2012, 7 (8), 1523-33.
58.
Karamanos, T. K.; Kalverda, A. P.; Thompson, G. S.; Radford, S. E., Visualization of transient protein-protein interactions that promote or inhibit
amyloid assembly. Mol Cell 2014, 55 (2), 214-26.
59.
Jahn, T. R.; Tennent, G. A.; Radford, S. E., A common beta-sheet architecture underlies in vitro and in vivo beta2-microglobulin amyloid fibrils. J
Biol Chem 2008, 283 (25), 17279-86.
60.
Orgel, J. P.; Irving, T. C.; Miller, A.; Wess, T. J., Microfibrillar structure of type I collagen in situ. Proc Natl Acad Sci U S A 2006, 103 (24), 90015.
61.
Merck, E.; Gaillard, C.; Gorman, D. M.; Montero-Julian, F.; Durand, I.; Zurawski, S. M.; Menetrier-Caux, C.; Carra, G.; Lebecque, S.; Trinchieri,
G.; Bates, E. E., OSCAR is an FcRgamma-associated receptor that is expressed by myeloid cells and is involved in antigen presentation and activation of
human dendritic cells. Blood 2004, 104 (5), 1386-95.

10

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

62.
Kim, N.; Takami, M.; Rho, J.; Josien, R.; Choi, Y., A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp
Med 2002, 195 (2), 201-9.
63.
Meyaard, L.; Hurenkamp, J.; Clevers, H.; Lanier, L. L.; Phillips, J. H., Leukocyte-associated Ig-like receptor-1 functions as an inhibitory receptor
on cytotoxic T cells. J Immunol 1999, 162 (10), 5800-4.
64.
Poggi, A.; Tomasello, E.; Ferrero, E.; Zocchi, M. R.; Moretta, L., p40/LAIR-1 regulates the differentiation of peripheral blood precursors to
dendritic cells induced by granulocyte-monocyte colony-stimulating factor. Eur J Immunol 1998, 28 (7), 2086-91.
65.
Ruggeri, Z. M., Platelets in atherothrombosis. Nat Med 2002, 8 (11), 1227-34.
66.
Moroi, M.; Jung, S. M., Platelet glycoprotein VI: its structure and function. Thromb Res 2004, 114 (4), 221-33.
67.
Kahn, M. L., Platelet-collagen responses: molecular basis and therapeutic promise. Semin Thromb Hemost 2004, 30 (4), 419-25.
68.
Zhou, L.; Hinerman, J. M.; Blaszczyk, M.; Miller, J. L.; Conrady, D. G.; Barrow, A. D.; Chirgadze, D. Y.; Bihan, D.; Farndale, R. W.; Herr, A. B.,
Structural basis for collagen recognition by the immune receptor OSCAR. Blood 2016, 127 (5), 529-37.
69.
Lebbink, R. J.; Raynal, N.; de Ruiter, T.; Bihan, D. G.; Farndale, R. W.; Meyaard, L., Identification of multiple potent binding sites for human
leukocyte associated Ig-like receptor LAIR on collagens II and III. Matrix Biol 2009, 28 (4), 202-10.
70.
Brondijk, T. H.; de Ruiter, T.; Ballering, J.; Wienk, H.; Lebbink, R. J.; van Ingen, H.; Boelens, R.; Farndale, R. W.; Meyaard, L.; Huizinga, E. G.,
Crystal structure and collagen-binding site of immune inhibitory receptor LAIR-1: unexpected implications for collagen binding by platelet receptor GPVI.
Blood 2010, 115 (7), 1364-73.
71.
Smethurst, P. A.; Joutsi-Korhonen, L.; O'Connor, M. N.; Wilson, E.; Jennings, N. S.; Garner, S. F.; Zhang, Y.; Knight, C. G.; Dafforn, T. R.;
Buckle, A.; MJ, I. J.; De Groot, P. G.; Watkins, N. A.; Farndale, R. W.; Ouwehand, W. H., Identification of the primary collagen-binding surface on human
glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood 2004, 103 (3), 903-11.
72.
Horii, K.; Kahn, M. L.; Herr, A. B., Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood 2006, 108
(3), 936-42.
73.
O'Connor, M. N.; Smethurst, P. A.; Farndale, R. W.; Ouwehand, W. H., Gain- and loss-of-function mutants confirm the importance of apical
residues to the primary interaction of human glycoprotein VI with collagen. J Thromb Haemost 2006, 4 (4), 869-73.
74.
Eichner, T.; Radford, S. E., Understanding the complex mechanisms of beta2-microglobulin amyloid assembly. FEBS J 2011, 278 (20), 3868-83.
75.
Verdone, G.; Corazza, A.; Viglino, P.; Pettirossi, F.; Giorgetti, S.; Mangione, P.; Andreola, A.; Stoppini, M.; Bellotti, V.; Esposito, G., The solution
structure of human beta2-microglobulin reveals the prodromes of its amyloid transition. Protein Sci 2002, 11 (3), 487-99.
76.
Ricagno, S.; Raimondi, S.; Giorgetti, S.; Bellotti, V.; Bolognesi, M., Human beta-2 microglobulin W60V mutant structure: Implications for
stability and amyloid aggregation. Biochem Biophys Res Commun 2009, 380 (3), 543-7.
77.
Esposito, G.; Corazza, A.; Viglino, P.; Verdone, G.; Pettirossi, F.; Fogolari, F.; Makek, A.; Giorgetti, S.; Mangione, P.; Stoppini, M.; Bellotti, V.,
Solution structure of beta(2)-microglobulin and insights into fibrillogenesis. Biochim Biophys Acta 2005, 1753 (1), 76-84.
78.
Trinh, C. H.; Smith, D. P.; Kalverda, A. P.; Phillips, S. E.; Radford, S. E., Crystal structure of monomeric human beta-2-microglobulin reveals
clues to its amyloidogenic properties. Proc Natl Acad Sci U S A 2002, 99 (15), 9771-6.
79.
Hodkinson, J. P.; Jahn, T. R.; Radford, S. E.; Ashcroft, A. E., HDX-ESI-MS reveals enhanced conformational dynamics of the amyloidogenic
protein beta(2)-microglobulin upon release from the MHC-1. J Am Soc Mass Spectrom 2009, 20 (2), 278-86.
80.
Rennella, E.; Corazza, A.; Fogolari, F.; Viglino, P.; Giorgetti, S.; Stoppini, M.; Bellotti, V.; Esposito, G., Equilibrium unfolding thermodynamics of
beta2-microglobulin analyzed through native-state H/D exchange. Biophys J 2009, 96 (1), 169-79.
81.
Rennella, E.; Corazza, A.; Giorgetti, S.; Fogolari, F.; Viglino, P.; Porcari, R.; Verga, L.; Stoppini, M.; Bellotti, V.; Esposito, G., Folding and
fibrillogenesis: clues from beta2-microglobulin. J Mol Biol 2010, 401 (2), 286-97.
82.
Armen, R. S.; Daggett, V., Characterization of two distinct beta2-microglobulin unfolding intermediates that may lead to amyloid fibrils of
different morphology. Biochemistry 2005, 44 (49), 16098-107.
83.
Fogolari, F.; Corazza, A.; Viglino, P.; Zuccato, P.; Pieri, L.; Faccioli, P.; Bellotti, V.; Esposito, G., Molecular dynamics simulation suggests
possible interaction patterns at early steps of beta2-microglobulin aggregation. Biophys J 2007, 92 (5), 1673-81.
84.
Corazza, A.; Rennella, E.; Schanda, P.; Mimmi, M. C.; Cutuil, T.; Raimondi, S.; Giorgetti, S.; Fogolari, F.; Viglino, P.; Frydman, L.; Gal, M.;
Bellotti, V.; Brutscher, B.; Esposito, G., Native-unlike long-lived intermediates along the folding pathway of the amyloidogenic protein beta2-microglobulin
revealed by real-time two-dimensional NMR. J Biol Chem 2010, 285 (8), 5827-35.
85.
Chiti, F.; De Lorenzi, E.; Grossi, S.; Mangione, P.; Giorgetti, S.; Caccialanza, G.; Dobson, C. M.; Merlini, G.; Ramponi, G.; Bellotti, V., A partially
structured species of beta 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis. J Biol Chem 2001, 276
(50), 46714-21.
86.
Chiti, F.; Mangione, P.; Andreola, A.; Giorgetti, S.; Stefani, M.; Dobson, C. M.; Bellotti, V.; Taddei, N., Detection of two partially structured
species in the folding process of the amyloidogenic protein beta 2-microglobulin. J Mol Biol 2001, 307 (1), 379-91.
87.
Esposito, G.; Michelutti, R.; Verdone, G.; Viglino, P.; Hernandez, H.; Robinson, C. V.; Amoresano, A.; Dal Piaz, F.; Monti, M.; Pucci, P.;
Mangione, P.; Stoppini, M.; Merlini, G.; Ferri, G.; Bellotti, V., Removal of the N-terminal hexapeptide from human beta2-microglobulin facilitates protein
aggregation and fibril formation. Protein Sci 2000, 9 (5), 831-45.
88.
Monti, M.; Amoresano, A.; Giorgetti, S.; Bellotti, V.; Pucci, P., Limited proteolysis in the investigation of beta2-microglobulin amyloidogenic and
fibrillar states. Biochim Biophys Acta 2005, 1753 (1), 44-50.
89.
Mangione, P. P.; Esposito, G.; Relini, A.; Raimondi, S.; Porcari, R.; Giorgetti, S.; Corazza, A.; Fogolari, F.; Penco, A.; Goto, Y.; Lee, Y. H.; Yagi,
H.; Cecconi, C.; Naqvi, M. M.; Gillmore, J. D.; Hawkins, P. N.; Chiti, F.; Rolandi, R.; Taylor, G. W.; Pepys, M. B.; Stoppini, M.; Bellotti, V., Structure,
folding dynamics, and amyloidogenesis of D76N beta2-microglobulin: roles of shear flow, hydrophobic surfaces, and alpha-crystallin. J Biol Chem 2013, 288
(43), 30917-30.
90.
Johnson, S. M.; Connelly, S.; Fearns, C.; Powers, E. T.; Kelly, J. W., The transthyretin amyloidoses: from delineating the molecular mechanism of
aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012, 421 (2-3), 185-203.
91.
Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; Bax, A., NMRPipe: a multidimensional spectral processing system based on UNIX
pipes. J Biomol NMR 1995, 6 (3), 277-93.
92.
Goddard, T. D.; Kneller, D. G. SPARKY 3, University of California, San Fransisco, 2008.
93.
Palmer, A. G.; Cavanagh, J.; Wright, P. E.; Rance, M., Sensitivity improvement in proton-detected two-dimensional heteronuclear correlation
NMR spectroscopy. Journal of Magnetic Resonance (1969) 1991, 93 (1), 151-170.
94.
Kay, L.; Keifer, P.; Saarinen, T., Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved
sensitivity. Journal of the American Chemical Society 1992, 114 (26), 10663-10665.

11

bioRxiv preprint doi: https://doi.org/10.1101/801522; this version posted October 11, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

95.
Hansen, D. F.; Vallurupalli, P.; Kay, L. E., An improved 15N relaxation dispersion experiment for the measurement of millisecond time-scale
dynamics in proteins. J Phys Chem B 2008, 112 (19), 5898-904.
96.
Millet, O.; Loria, J. P.; Kroenke, C. D.; Pons, M.; Palmer, A. G., The static magnetic field dependence of chemical exchange linebroadening
defines the NMR chemical shift time scale. Journal of the American Chemical Society 2000, 122 (12), 2867-2877.

12

